A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis
Rituximab has been used in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) since 2003. Our objective was to describe outcomes and adverse events following rituximab since that time in an inception cohort.doi:10.17615/th89-3a59 fatcat:gmzoyosq4ffszmndqhtxve5tue